TERENCE JOHN CAMPBELL AM

Curriculum Vitae

Date of Birth: 9th December, 1949

Address: University Department of Medicine, St Vincent’s Hospital, Darlinghurst, Sydney, 2010

QUALIFICATIONS

1972 Bachelor of Science (Medicine) 1st Class Honours, University of New South Wales

1975 Bachelor of Medicine, Bachelor of Surgery, 1st Class Honours, University of NSW

1981 Fellow of the Royal Australasian College of Physicians

1983 Doctor of Philosophy, University of Oxford

1990 Fellow, American College of Cardiology

1991 Fellow, European Society of Cardiology

1991 Doctor of Medicine, University of NSW

1994 Fellow, Council on Clinical Cardiology, American Heart Association

PRESENT APPOINTMENTS

1998- Professor of Medicine, University of New South Wales and

Head – University Department of Medicine, St Vincent’s Hospital, Sydney

2003- Deputy Director, Victor Chang Cardiac Research Institute

2004- 6 Associate Dean (Research), Faculty of Medicine, UNSW

2006- Senior Associate Dean, Faculty of Medicine, UNSW

PREVIOUS APPOINTMENTS

1975-77 Intern and Resident Medical Officer, St. Vincent's Hospital

1978-80 Cardiology Registrar, St. Vincent's Hospital

1980-82 Nuffield Dominions Demonstrator, University Department of Pharmacology, Oxford, England; also Honorary Senior Registrar (1980-81), and Honorary Clinical Assistant (1982), Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford

CV - T. Campbell 1

1983-84 Cardiology Research Fellow, Honorary Deputy Director, Coronary Care Unit, St. Vincent's Hospital

1984-85 National Health and Medical Research Council Senior Research Officer, School of Medicine, University of NSW

1985-86 Lecturer, School of Physiology & Pharmacology, University of NSW

July 1986 Promoted to Senior Lecturer with tenure

Aug 1987 Appointed Senior Lecturer in Medicine (conjoint) at St. Vincent's Hospital

1990-93 Chairman, Department of Cardiology, St. Vincent's Hospital

1990-98 Senior Staff Specialist in Clinical Pharmacology and Cardiology, St. Vincent's Hospital

Deputy Director, Dept. of Clinical Pharmacology, St. Vincent's Hospital

Director, Coronary Care Unit, St. Vincent's Hospital

Associate Professor (Conjoint), Schools of Medicine, and of Physiology & Pharmacology, UNSW

1995- Faculty Member, Victor Chang Cardiac Research Institute

PRIZES/AWARDS

Staff Association Prize for Proficiency in the Clinical Years of the Medical Course 1975

Shared prize for Psychiatry on Graduation 1975

Awarded Membership of the Order of Australia (AM), 2003

MEMBERSHIP OF SOCIETIES

1978-86 Associate Member, Cardiac Society of Australia and New Zealand

1986- Cardiac Society of Australia and New Zealand -Honorary Secretary 1991-96-President 2000-2002

1985- Australian Physiological and Pharmacological Society

2001 Australian Society for Medical Research

1990- American College of Cardiology (Fellow)

1992- Australian Society for Clinical & Experimental Pharmacology and Toxicology

1994- American Heart Association (International Fellow)

1995- International Society of Cardiovascular Pharmacotherapy 1995- Heart Rhythm Society (North America)

CV - T. Campbell 2

COMMITTEES St. Vincent’s Hospital/University of NSW:

1990- Drug Committee, St. Vincent's Hospital (Deputy Chairman, 1992-2002; Chairman 2002-)

1990-93 Chairman, Dept of Cardiology, St. Vincent's Hospital (Rotating 3 year position)

1990-93 Medical Board Executive, St. Vincent's Hospital (elected representative of Division of Medicine)

1992- Special Access Scheme for Unmarketed Drugs - Delegate for St. Vincent's

1994- Research Ethics Committee, St. Vincent's Hospital (Chairman 1996-8)

1996- Management Committee, St Vincent's Clinical Trials Centre

1996-2000 Cardiopulmonary Resuscitation Committee

1998- Member, Campus Medical Council, St. Vincent’s Hospital

1999- Member, Board of St. Vincent’s Clinic

1999- Member, Medical Staff Appointments & Credentials Committee, St. Vincent’s Hospital(Chairman from 2001).

1999- Member, Research Committee, Faculty of Medicine, UNSW

2001- Chairman, Patient Safety Committee, St Vincent’s Hospital

External (Non-Government):

1986 – 2003 Scientific Subcommittee, Cardiac Society of Australia and New Zealand.

1989- Member, NHMRC Regional Grants Interviewing Committees (Adelaide, 1989;Adelaide/Perth 1991; Melbourne 1992;

1991-9 Education Committee, National Heart Foundation (NSW); Chairman from 1996

1991-96 Specialist Advisory Committee (Cardiology), Royal Australasian College of Physicians

1992- Specialist Registry of Overseas Referees, Hong Kong Research Grants Council

1994- Subcommittee on Cardiovascular diseases, Australian Clinical Casemix Committee

1995- Therapeutics Advisory Committee, Royal Australasian College of Physicians (Chairman from 1996)

CV - T. Campbell 3

1995-8 Maintenance of Professional Standards Committee, RACP

1995-2002 Specialties Board, RACP

1995-6 Chairman, Pharmaceuticals and Devices Committee, Cardiac Society, ANZ

1996-9 University of NSW Human Ethics Committee

1996-2008 Member, Board of NSW Division of National Heart Foundation (Deputy President 2003-4)

2002-6 Member National Board, National Heart Foundation of Australia

2007- Member, Scientific Advisory Committee, 45 and Up Study

External (Government):

1992-98 Member, Australian Drug Evaluation Committee (ADEC)

1995-96 NSW Health Department Ad Hoc Committee on Guidelines for CardiacCatheterization Laboratories

1996-97 Member, Reference Committee for Review of Therapeutic Goods Administration

1997-98 Member, Advisory Committee, National Prescribing Service, Dept. Health & Family Services (Representing RACP).

1997-8 Member Education Advisory Committee for Therapeutic Group Premiums initiative of Government (Representing RACP)

2001- Member, Pharmaceutical Benefits Advisory Committee (PBAC).

2003 Member, Expert Committee on Complementary Medicines in the Health System

2004 Co-Chair, Govt Cttee to review Statin prescribing in Australia

EDITORIAL BOARDS, REFEREEING, ETC

Regular Referee for:- Medical Journal of Australia, Circulation, Circulation Research, The Journal of Molecular and Cellular Cardiology, The European Journal of Pharmacology, the British Journal of Pharmacology, and Cardiovascular Drugs & Therapy

Editorial Board, "Modern Medicine" of Australia, "Heart", U.K., and J Cardiovasc Pharmacol Ther., USA

CV - T. Campbell 4

CURRENT RESEARCH INTERESTS - LABORATORY

Current Research staff :

Dr Jamie Vandenberg NHMRC R D Wright Fellow

Dr Cath Clarke Post-doctoral Fellow

Dr Jing Ting Zhao Post-doctoral Fellow

Dr Adam Hill Post-doctoral Fellow

Ken Wyse, BSc Research Assistant

Jane Bursill, BTC Technical Officer

Current Projects:

i) Proarrhythmic Effects of Cardioactive Agents

These studies use the same model as outlined in (i) above, as well as the transfected mammalian cell line models outline below. Essentially we are studying the ability of drugs used as antiarrhythmic agents, as well as some antihistamines, antipsychotic agents, antidepressants etc which are known to occasionally provoke tachyarrhythmias.

ii) Studies of Isolated Human Potassium Channels

These comprise the largest part of our current work. We use transfected ion channels- both stable transfections into mammalian cell lines and transient transfections into Xenopus oocytes. We are studying a number of questions to do with the structure-function relationships of various channels, including gating mechanisms and drug-binding properties where relevant. Channels under study include “HERG” the drug-sensitive delayed rectifier cardiac potassium channel and others.

iii) Studies of a Novel Chloride Channel (NCC27)

This work is in collaboration with Prof Sam Breit at St Vincents, and also being carried out by Drs Tonini and Mazzanti from Milan. It involves the electrophysiological characterisation of a novel protein cloned by Dr Breit in the Centre for Immunology which codes for a chloride channel which is preferentially expressed on the nuclear membrane rather on the plasma membrane. We are studying this transfected into CHO- K1 cells, and nuclear membranes .

PEER-REVIEWED EXTERNAL RESEARCH SUPPORT

Year Source Title Amount ($)

1980 Nuffield Nuffield Dominions Demonstratorship 13,000

1981 Dominions 15,000

1982 Scheme, U.K. 20,000

CV - T. Campbell 5

1984 NHMRC Mechanisms of action of Class I 48,818

1985 “ antiarrhythmic drugs 45,185

1986 NHMRC Electrophysiologic effects of Class I 27,577

1987 " antiarrhythmic drugs on heart cells 24,108

1988 " 24,508

1986 Ramaciotti Class I antiarrhythmic drug effects on sinus node 12,300

1988 NHF Patch clamp study of Class I antiarrhythmic drug 15,000effects

1989 Ramaciotti Antiarrhythmic drug effects on isolated human 15,142heart cells

1990 NHMRC Antiarrhythmic drug action in simulated ischaemia 31,500

1991 " 32,500

1992 " 34,000

1990 NHF Arrhythmogenic effects of antiarrhythmic drugs 36,0831991 " in canine Purkinje fibres 39,617

1992 " 43,312

1992 NHF Patch-clamp study of ion channels in cardiac 61,000

1993 " myocytes 68,700

1993 NHF Arrhythmogenic effects of cardioactive drugs 33,829

1994 " 39,223

1993 Ramaciotti Patch-clamp study of ion channels in vascular 15,000smooth muscle cells

1992-3 CRC CRC for Cardiac Technology 18,000

1994 NHMRC Antiarrhythmic drug action in simulated 50,054

1995 " ischaemia 50,054

1996 " 50,054

1995 NHF Cellular effects of antiarrhythmic drugs 38,925

1996 " 38,925

1995-96 NHF Scholarship (P West) 44,000

1997-99 NHF Scholarsip (C. Singleton) 66,000

1997-99 NHMRC Scholarship (B Walker) 66,000

1997 NHMRC Modulation of antiarrhythmic 51,9051998 " " Drug action by ischaemia 52,8041999 " " and tachycardia 52,804

1998 NHF Electrophysiology & pharmacology of the 49,5001999 human transient outward potassium current 51,000

Kv 4.3.

1998 Ramaciotti Studies of potassium channels in human cardiac myocytes 15,000

1998-2000 NHMRC Scholarship (H. Tie) 66,000

1999-2001 ARC A mathematical and experimental analysis of 173,900vagal tachycardia

CV - T. Campbell 6

2000 Ramaciotti Ion channels in the pathogenesis and treatment of cardiac, vascular and inflammatory diseases 18,000

2000–2001 NHF Electrophysiology and pharmacology of thehuman cardiac potassium channel, HERG 99,000

2000–2002 NHMRC The human cardiac transient outward potassiumchannel Kv4.3: A study of its pharmacology andmodulation by disease states 196,254

2001-2003 NHMRC Structure function relationship of ncc27, a novel nuclear chloride ion channel protein 240,000

2002-4 NHMRC HERG K+ channels:Molecular basis of gating 435,000

2002-4 NHMRC Transition of NCC27 (CLIC1) chloride ion channels 300,000 from the soluble to the membrane bound form

2002-3 NHF The molecular basis of refractoriness in the heart 97,576

2004-6 NHMRC The in vivo and in vitro biology of the novel intracellular ion channel CLIC1 (NCC27) 425,250

2004-6 NHMRC NHMRC Scholarship (Subbiah) 80,000

2005-7 NHMRC Molecular basis of voltage-dependent activation 432,750of HERG K+ channels

2005-7 ARC Characterisation of two pore domain potassium 277,000 channels: structure function studies of the M1-P1 loops of TASK channels. Clarke, Vandenberg, Campbell, Torres, Mathie

2007-9 NHMRC The feasibility and impact of cardiovascular 799,346absolute risk assessment in general practice . Harris, Zwar, Campbell et al

PEER-REVIEWED INTERNAL SUPPORT

Year Source Title Amount ($)

1983 St. Vincent's Hospital Research Fellowship 16,000

1983 " Research Grant 10,000

1983 " (MPU) Research Grant (Equipment) 20,000

1993 " Antiarrhythmic drug action in simulated 25,000ischaemia

1993 St. Vincent's Clinic Intracellular control mechanisms for ion 7,338channels in smooth muscle

1994 St. Vincent's Hospital Inhibition of potassium channels by 20,000antiarrhythmic drugs

1994 St. Vincent's Clinic Effectiveness of antiarrhythmic drugs 24,885

CV - T. Campbell 7

1995 St. Vincent's Hospital Cardiac ATP-sensitive potassium channels 12,000

1995 St. Vincent's Clinic Role of ion channels in vascular endothelial

cell biology 33,000

1996 St. Vincent's Clinic Drug actions on cardiac potassium channels 20,000

1997 St Vincent's Clinic Differential proarrhythmic actions 20,000 of antidepressant drugs

2000 St Vincents Clinic Possible role for potassium channels in heart 80,000attack

2003 St Vincents Clinic Structure of the HERG K channel binding site 20,000

2004 St Vincents Clinic Binding to HERG K channels 20,000

2007 St Vincents Clinic Protein trafficking defects as a cause of congenital long QT syndrome 25,000

2008 St Vincents Clinic The state dependence of drug binding to the 100,000human ether-a-go-go-related gene K+ channel

INDUSTRY-SPONSORED RESEARCH FUNDING

Year Source Title Amount ($)

1988 E. R. Squibb Basic study of captopril 2,000

1988 Reckitt & Colman Study of amiodarone 1,000

1992 Boehringer-Ingelheim Zatebradine Trial 10,000

1993 " " 10,000

1992 Eli Lilly Unspecified 5,000

1993 Winthrop Laboratories "CAPRIE" Trial 15,000

1993 Boehringer - Ingelheim "GUSTO" Trial 12,104

1994 Boehringer - Ingelheim Zatebradine Trial 7,417

1994 Boehringer - Ingelheim "GUSTO" Trial 2,430

1994 Sanofi-Winthrop "CAPRIE" Trial 39,300

1994 Bristol-Myers Squibb "SWORD" Trial 7,022

1994 Pfizer Dofetilide Trial 7,000

1994 Bristol-Myers Squibb "LIPID" Trial 3,960

1995 Winthrop CAPRIE 17,050

1995 Pfizer Dofetilide 10,500

1995 "GUSTO" IIb 5,216

1995 Bristol-Myers Squibb LIPID 4,164

CV - T. Campbell 8

1996 Bristol-Myers Squibb LIPID 3,840Hoechst-Marion Roussel Electrophysiology of Macrolide 25,000

Antibiotics

1996 Roche PARAGON 2,952

1997 " " 2,115

1997 Bristol Myers Squibb LIPID 8,040

1997 Pfizer Dofetilide 900

1997 Sanofi "FRAXIS" 4,250

1998 Smith Kline Beecham “CAPRICORN” 17,000

1998 Sanofi “FRAXIS” 4,250

1999 Bristol Myers Squibb LIPID 4,700

1999 Duke University Research SYMPHONY 4,000

1999 Servier PERINDOPRIL Trial 8,000

1999 Smith Kline Beecham CAPRICORN 8,300

2001 Duke University SYMPHONY trial 3000

2002 Bristol Myers Squibb PACT 5225

2002 Pharmacia EPHESUS 3344

2002 WARF Royalty 7844

CV - T. Campbell 9

INVITED LECTURES & SEMINARS

1986 Co-chairman of a session on anti-arrhythmic drugs at International Society for Heart Research Annual Scientific Meeting, Melbourne

1987 Invited speaker and co-ordinator of Symposium entitled "Anti-Arrhythmic Drugs", held as part of Tenth International Congress of Pharmacology, Sydney, August 1987

1988 Invited speaker in Symposium entitled "The Role of Membranes in Regulating Muscle Contraction", held as part of Bicentennial Meeting of Australasian Physiological & Pharmacological Society, A.N.U. February 1988

1988 Invited lecture on: "New insights into the mechanisms of action of antiarrhythmic drugs at the level of the cell membrane": In a Symposium on "New Developments in Antiarrhythmic Drugs" at the Bicentennial Meeting of the Cardiac Society of Australia & New Zealand & the Royal Australasian College of Physicians, Sydney, 8 May 1988

1988 Invited to present a poster at International Conference on Molecular & Cellular Mechanisms of Antiarrhythmic Agents, Nashville, USA

1989 Invited by Japanese Circulation Society to give a lecture on the Clinical Relevance of the Subclassification of Class I Antiarrhythmic drugs at a Satellite Symposium of their Annual Scientific Meeting, Nagoya, March 1989, and to speak at a scientific meeting in Tokyo during the same visit

1992 Invited Speaker, Cardiac Society, Satellite Meeting, Melbourne

1994 Invited Speaker, Saudi Heart Association Annual Scientific Sessions, Saudi Arabia

1994 Invited Chairman, International Society of Hypertension, Satellite Meeting on Heart Failure, Melbourne

1994 Invited Speaker, 24th Annual Scientific Session, Republic of China Society of Cardiology, Taipei, May 1st

1995 Invited Speaker, (3 Seminars) Cardiac Society Annual Scientific Meeting, Canberra

1996 Invited Speaker and Chair (2 sessions) International Society of Cardiovascular Pharmacotherapy Meeting, Sydney, February

1996 Invited Speaker, North American Congress of Clinical Toxicology, Portland, Oregon - October 12

1996 Invited Speaker, University of Oregon, Medical Center Grand Rounds, Emergency Department - October 15

1996 Invited Speaker, Hennepin County Medical Center, Medical Grand Rounds - October 16

1997 Invited Speaker, Asian Pacific Symposium on Pacing and Electrophysiology, Delhi, India, - October 25

2003 Invited Chairman, North American Society of Pacing & Electrophysiology

2001 Invited speaker, International Cardiology meeting, Beijing

CV - T. Campbell 10

2002 Invited speaker, Great Wall of China Cardiology meeting, Beijing

2003 Invited Chair, American College of Cardiology, Annual scientific Sessions, Chicago

2003 Invited speaker Cardiac Society of ANZ Annual Scientific meeting

2004 Invited Speaker and Chair of Symposium at World congress of Clinical Pharmacology and toxicology, Brisbane, August 5

2006 Invited speaker Cardiac Society of ANZ Annual Scientific meeting

2006 Invited speaker-Symposium World Congress of Cardiology, Barcelona, Sept 2006

TEACHING EXPERIENCE

Undergraduate Medical and Science Students

Twenty five years of extensive experience in lecturing and tutoring on campus in Physiology, Pharmacology and at St Vincents Hospital in Therapeutics and small group tutorials for Clinical Medicine

Research Student Supervision   (As primary supervisor)

Present Mark Perrin MB BS (PhD student about to enrol)

Past

1986 Regan Pallandi, BSc (Hons)

1988 Paul Hemsworth, BSc (Hons)

1990-93 Victor Ye, MSc (Awarded 1993)

1994-96 Paul West M.D. (Awarded 1998)

1997-2000 Bruce Walker PhD (Awarded 2000)

1997-2001 Cameron Singleton, M.D (Awarded 2002)

1998-2002 Hui Tie, MD (Awarded 2003)

2000-2003 Suresh Singarayar MD (Awarded 2004)

2002-5 Raj Subbiah MB,BS, PhD Student (awarded 2005)

ADMINISTRATIVE EXPERIENCE

Chairman, Cardiology Department, St. Vincent's Hospital, 1990-93 (three-year, rotating appointment).

Director, Coronary Care Unit, St. Vincent's Hospital, 1990-8

Deputy Director, Clinical Pharmacology Department, St. Vincent's Hospital, 1990-

CV - T. Campbell 11

Honorary Secretary, Cardiac Society of Australia & New Zealand, 1991-96

President, Cardiac Society of Australia & New Zealand, 2000-2.

Chairman, Pharmaceuticals and Devices Committee, Cardiac Society, ANZ, 1995-96

Chairman, Research Ethics Committee St. Vincent's Hospital, 1996 –99.

Chairman, Education Committee NSW Division of National Heart Foundation, 1996-9.

Chairman, Therapeutics Advisory Committee RACP, 1996-2001.

Chair, Patient safety Cttee, St Vincents Hospital 2002-6

Chair, Education Cttee, St Vincents Hospital, 1998-

Chair, Medical Staff Appointments and Credentials Cttee, St Vincents, 2000-

Head of School, St Vincents Clinical School 2000-

Associate Dean(Research), Faculty of Medicine 2004-

CV - T. Campbell 12

PUBLICATIONS

FULL PAPERS IN PEER-REVIEWED JOURNALS OR BOOKS

As at August 2007: Total citations=1993 (incl 144 self-citations); h-index=20 with 4 papers having>100 citations [Details saved on separate version of my papers]

1. Campbell T and Heath,T. Intrinsic contractility of lymphatics in sheep and in dogs. Quart J Expr Physiol 1973; 58: 207-17.

2. Hugh TB and Campbell TJ. Contact cholangiography. Am J Surgery 1976; 132: 562-4.

3. Campbell TJ, Hickie JB, Michell G and O'Rourke MF. Nifedipine in the treatment of life threatening Prinzmetal angina. Aust NZ J Med 1979; 9: 293-4.

4. Campbell TJ and Morgan JJ. Treatment of atrial arrhythmias after cardiac surgery with intravenous disopyramide. Aust NZ J Med 1980; 10: 644-9.

5. O'Rourke MF, Norris RN, Campbell TJ, Chang VP and Sammel NL. Randomized controlled trial of intra-aortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol 1981; 47: 815-20.

6. Campbell TJ and Vaughan Williams EM. Electrophysiological and other effects on rabbit hearts of CCI 22277, a new steroidal antiarrhythmic drug. Br J Pharmacol 1982; 76: 337-34.

7. Vaughan Williams EM, Millar JS and Campbell TJ. Electrophysiological effects of labetolol on rabbit atrial, ventricular and Purkinje cells in normoxia and hypoxia. Cardiovasc Res 1982; 16: 233-9.

8. Vaughan Williams EM and Campbell TJ. The effects of nadolol on various cardiac tissues in normoxia and on atrial muscle in simulated ischaemia. Eur J Pharmacol 1982; 83: 161-9

9. Campbell TJ. Voltage-and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two steroidal anti-arrhythmic drugs, CCI 22277 and Org 6001. Br J Pharmacol 1982; 77: 541-8.

10. Campbell TJ. Studies on the mode of action of cardioactive drugs in animals and man. DPhil Thesis, Oxford University, 1982.

11. Campbell TJ.and Vaughan Williams EM. Voltage-and time -dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials of two new anti-arrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 1983; 17: 251-8

12. Campbell TJ. Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea-pig ventricular action potentials by mexiletine, disopyramide and encainide. J Cardiovasc Pharmacol 1983; 5: 291-6.

13. Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983; 17: 344-52.

CV - T. Campbell 13

14. Campbell TJ. Importance of physico-chemical properties in determining the kinetics of the effects of Class I antiarrhythmic drugs on maximum rate of depolarisation in the guinea-pig ventricle. Br J Pharmacol 1983; 80: 33-40.

15. Campbell TJ. Antiarrhythmic agents. Med J Aust 1984; 141: 718-23.

16. Gavaghan TP, Feneley MP, Campbell TJ and Morgan JJ. Atrial tachyarrhythmias after cardiac surgery: results of disopyramide therapy. Aust NZ J Med 1985; 15: 27-32.

17. Campbell TJ, Gavaghan TP and Morgan JJ. Intravenous sotalol for treatment of atrial fibrillation and flutter after cardiopulmonary bypass: comparison with disopyramide and digoxin in a randomized trial. Br Heart J 1985; 54: 86-90.

18. Gavaghan TP, Kelly RP, Kuchar DL, Hickie JB and Campbell TJ. The prevalence of arrhythmias in hypertrophic cardiomyopathy: role of ambulatory monitoring and signal-averaged electrocardiography. Aust NZ J Med 1986; 16: 666-670.

19. Kuchar DL, Campbell TJ and O'Rourke MF. Long term survival after counterpulsation for medically refractory heart failure complicating myocardial infarction and cardiac surgery. Eur Heart J 1987; 8: 490-502.

20. Campbell TJ. Cellular electrophysiological effects of d- and dl -sotalol in guinea-pig sinoatrial node, atrium and ventricle and in human atrium. Br J Pharmacol 1987; 90: 593-599.

21. Campbell TJ. Differing electrophysiological effects of Class IA, IB and IC antiarrhythmic drugs on guinea-pig sinoatrial node. Br J Pharmacol 1987; 91: 395-401.

22 Pallandi RT, Perry MA and Campbell TJ. Proarrhythmic effects of an oxygen-derived free radical generating system on action potentials recorded from guinea-pig ventricular myocardium: a possible cause of reperfusion induced arrhythmias. Circ Res 1987; 61: 50-54.

23. Pallandi RT and Campbell TJ. Resting, and rate-dependent depression of Vmax of guinea-pig

ventricular action potentials by amiodarone and desethylamiodarone. Br J Pharmacol 1987; 92: 97-103.

24. Campbell TJ. A possible role for free radicals in cardiac reperfusion phenomena. (Editorial). Aust NZ J Med 1987; 17: 459-460.

25. Pallandi RT and Campbell TJ. Selective depression of conduction of premature action potentials in canine Purkinje fibres by class IB antiarrhythmic drugs: Comparison with IA and IC drugs. Cardiovasc Res 1988; 22: 171-178.

26. Gavaghan TP, Keogh AM, Kelly RP, Campbell TJ, Thorburn C and Morgan JJ. Flecainide versus digoxin/disopyramide for acute atrial tachyarrhythmias after cardiopulmonary bypass. Br Heart J 1988; 60: 497-501.

27. Vaughan Williams EM and Campbell TJ (Eds). Handbook of Experimental Pharmacology. Volume: Antiarrhythmic Drugs, Springer-Verlag, Berlin, 1989.

28. Campbell TJ. Subclassification of antiarrhythmic drugs. In: Handbook of Experimental Pharmacology. Volume: Antiarrhythmic Drugs; E, Vaughan Williams & TJ Campbell (Eds). Springer-Verlag, Berlin, 1989: 135-155.

29. Campbell TJ. Pharmacology of Class Ia Agents. In: Handbook of Experimental Pharmacology, Volume: Antiarrhythmic Drugs; EM Vaughan Williams & TJ Campbell (Eds), Springer-Verlag, Berlin, 1989: 175-199.

CV - T. Campbell 14

30. Campbell TJ. Clinical Efficacy for Arrhythmias of Cardiac Glycosides. In: Handbook of Experimental Pharmacology, Volume: Antiarrhythmic Drugs; EM Vaughan Williams & TJ Campbell (Eds), Springer-Verlag, Berlin, 1989: 565-568.

31. Campbell TJ. Characteristics of cardiac action potentials in marsupials. J Comp Physiol B 1989; 158: 759-762.

32. Hemsworth PD and Campbell TJ. Resting and rate-dependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by metabolites of encainide. Br J Pharmacol 1989; 97: 619-625.

33. Hemsworth PD, Pallandi RT and Campbell TJ. Cardiac electrophysiological actions of captopril: lack of direct antiarrhythmic actions. Br J Pharmacol 1989; 98: 192-196.

34. Campbell TJ. Antiarrhythmic Drugs. In: Eckert GM, Gutmann F & Keyser H (Eds): Electropharmacology, C.R.C. Press, Florida, 1990: 247-268.

35. Campbell TJ. Antiarrhythmic drugs - mechanisms of action. Aust Prescr 1990; 13: 15-19.

36. Campbell TJ, Hemsworth PD. Selective depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by amiodarone and lignocaine in simulated ischaemia: Comparison with encainide. Clin Exp Pharmacol Physiol 1990; 17: 135-145.

37. Campbell TJ. Pro-arrhythmic action of antiarrhythmic drugs: A review. Aust NZ J Med 1990; 20:

275-282.

38. Campbell TJ, Wyse KR and Hemsworth PD. Effects of hyperkalemia, acidosis and hypoxia on the depression of maximum rate of depolarization by Class I antiarrhythmic agents in guinea-pig myocardium: differential actions of Ib and Ic agents. J Cardiovasc Pharmacol 1991; 18: 51-59.

39. Campbell TJ, Wyse KR and Pallandi R. Differential effects on action potential duration of Class

Ia, Ib and Ic antiarrhythmic drugs: modulation by stimulation rate and extracellular K+

concentration. Clin Exp Pharm Physiol 1991; 18: 533-541.

40. Campbell TJ. Treatment of atrial fibrillation: Time for change? Med J Aust 1992; 157: 78-80.

41. Campbell TJ. Recent developments in the pharmacotherapy of cardiac failure. Med J Aust 1992; 157: 292-294.

42. Campbell TJ. Subclassification of Class I antiarrhythmic drugs: Enhanced relevance after CAST. Cardiovasc Drugs Ther 1992; 6: 519-528.

43. Ye V, Wyse KR and Campbell TJ. Lidocaine shows greater selective depression of myocardium in simulated ischemia than propafenone: Possible implications for proarrhythmia. J Cardiovasc Pharmacol 1993; 21: 47-55.

44. Wyse KR, Ye V and Campbell TJ. Action potential prolongation exhibits simple dose -dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: Implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol 1993; 21: 316-322.

45. Campbell TJ. Sodium channel blockers. In: Singh BN, Dzau VJ, Vanhoutte PM and Woosley RL (Eds); Cardiovascular Pharmacology and Therapeutics, Churchill Livingstone, New York. 1994; Chapter 41: 645-663.

CV - T. Campbell 15

46. Wyse KR, Ye V and Campbell TJ. Effects of hyperkalaemia on the depression of maximum rate of depolarization by Class I antiarrhythmic agents in guinea-pig myocardium. Br J Pharmacol 1993; 108: 255-261.

47. Campbell TJ. Antiarrhythmic drugs. Med J Aust 1994; 160: 202-205.

48. Campbell TJ. Class III antiarrhythmic action: The way forward? Med J Aust 1993; 158: 732-733.

49. Campbell TJ. Digitalis for patients with heart failure in sinus rhythm? Med J Aust 1993; 159: 647-649.

50. Martin DK, Nakaya Y, Wyse KR and Campbell TJ. Effects of disopyramide and flecainide on the kinetics of inward rectifier potassium channels in rabbit heart muscle. Br J Pharmacol 1994; 111: 873-879.

51. Bursill JA, Wyse KR and Campbell TJ. Quinidine but not disopyramide prolongs cardiac Purkinje fiber action potentials following a pause. J Cardiovasc Pharmacol 1994; 23: 833-837.

52. Campbell TJ. Antiarrhythmic drug therapy: Future directions. J Saudi Heart Assoc 1994; 6: 113-122.

53. Campbell TJ. Treatment of atrial fibrillation. Aust Family Physician 1994; 23: 924-933.

54. Nakaya, Y. Martin, D.K. Campbell, T.J. Effect of E-4031, Sotalol and MS-551 on single inward-rectifier potassium channels in rabbit heart cells. Jpn. Heart J. 1996; 35 (Supp.1) 275-276.

55 Martin DK, Nakaya Y, Wyse KR, Bursill JA, West PD, Campbell TJ. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by a novel antiarrhythmic agent, MS-551. Pharmacol. Toxicol. 1995; 77: 65-70

56. Martin DK, Bootcov MR, Campbell TJ, French PW, Breit SN. Human macrophages contain a stretch-sensitive potassium channel that is activated by adherence and cytokines . J Membrane Biol 1995; 147: 305-315

57. Campbell TJ. Proarrhythmia: Cellular mechanisms. J Saudi Heart Assoc 1996; 8: 10-20.

58. West P.D., Bursill J.A., Wyse K.R., Martin D.K., Campbell T.J. Effect of the class III antiarrhythmic agent E-4031 on the ATP sensitive potassium channel in rabbit ventricular myocytes. Pharmacol.Toxicol. 78, 89-93, 1996.

59. Pallandi R.T., Lovell N.J., Campbell T.J. Class III antiarrhythmic effects of dofetilide in rabbit atrial myocardium. J.Cardiovasc.Pharmacol.Therapeut. 1996; 1: 229-234.

60 Campbell T.J. Proarrhythmic complications of sotalol (Invited Editorial). Aust NZ J Med 1996; 26: 147-149.

61. Campbell, T.J. Is this Arrhythmia Significant? Aust Family Physician 1996; 25: 1045-1050.

62. Campbell, T.J Beta-Blockers for ventricular arrhythmia: Have we underestimated their value? Aust. N.Z.J. Med. 1996; 26: 689-696.

63. West P.D. Bursill J.A. Wyse K.R. Martin D.K. Campbell T.J. (1996). Effect of dofetilide and D-sotalol on the ATP-sensitive potassium channel of rabbit ventricular myocytes. J. Cardiovasc. Pharmacol. Therapeut. 1996; 1: 307-312.

64. Wyse K.R, Bursill J.A, and Campbell T.J. Differential effects of antiarrhythmic agents on post pause repolarisation in cardiac Purkinje fibres. Clin Exp Pharm Phys 1996; 23: 825-829.

CV - T. Campbell 16

65. Martin, D.K. Boneham, G.C. Pirie, B.L. Collin, H.B. & Campbell, T.J. Chloride ion channels are associated with adherence of lymphatic endothelial cells. Microvasc. Res. 1996; 52: 200-209.

66. Campbell T.J. Antiarrhythmic Drugs. In: Thompson,P.(Ed) - Manual of Coronary Care, Churchill Livingstone, London, 1997; pp. 225-244.

67. Nakaya, Y. Martin, D.K. Campbell, T.J. The novel class III antiarrhythmic agent MS-551 blocks the cardiac inward rectifier with greater potency than sotalol or E-4031: possible relevance to reverse use-dependence. J.Cardiovasc. Pharm Therapeut. 1997; 2: 39-46

68. Firkin, F. Campbell, T. Safety of chloramphenicol eye drops. Aust.N.Z.J. Ophthal. 1997; 25: 3.

69. Campbell, T.J. Anticoagulation for atrial fibrillation. Mod. Medicine, 1997; 40: 34 - 38

70. Valenzuela,S.M. Martin,D.K .Por,S.B. Robbins,J.M. Bootcov,M.R. Schofield,P.R. Campbell, T.J. Breit,S.N. Molecular cloning and expression of a chloride ion channel of cell nuclei. J.Biol.Chem. 1997; 272: 12575-12582.

71. Campbell, T.J. Antiarrhythmic Drugs in: Principles of Medical Biology, Vol. 8B: Molecular and Cellular Pharmacology, Bittar E.E. (ed). JAI Press Greenwich, CT, USA 1997. pp 519 - 527

72. West, P.D. Martin, D.K. Bursill, J.A. Wyse, K.R. Campbell, T.J. Modulation of the electrophysiologic actions of E-4031 and dofetilide by hyperkalemia and acidosis in rabbit ventricular myocytes. J.Cardiovasc.Pharmacol.Ther. 1997; 2: 205-212

73. Campbell, T.J. The place of amiodarone: an overview of the four recent large amiodarone trials. A.N.Z. J.Med.27, 1997; 582-590.

74. West PD, Martin DK, Bursill JA, Wyse KR, Campbell TJ. Comparative study of the effects of erythromycin and roxithromycin on action potential duration and potassium currents in canine Purkinje fibers and rabbit myocardium. J Cardiovasc Pharmacol. Therapeut.3;. 1998; 29-36.

75. Campbell TJ and Williams KM. Therapeutic Drug Monitoring: Antiarrhythmic Drugs. Br J Clin Pharmacol; 1998; 46: 307-319.

76. Day RO, Chalmers DRC, Williams KM, Campbell TJ. The death of a healthy volunteer in a human research project:implications for Australian clinical research. Med J Aust; 1998; 168: 449-451.

77. Martin D, Bursill J, Qui M, Breit SN and Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. The Lancet, 1998; 351,1858-1859.

78. Campbell TJ, Pentel PR, Straka RJ, Swanson AL and Parra D, Antiarrhythmic Drug Poisoning; In:"Intensive Care Medicine" R.S. Irwin, F.B. Cerra, and J.M Rippe, (eds.), Lippincott-Raven, Boston, 1999; pp 1494-1511.

79. Walker BD, Valenzuela SM, Singleton CB, Tie H, Bursill JA, Wyse KR, Qiu MR, Breit SN, Campbell TJ. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate. Brit J Pharmacol 1999; 127(1): 243-251.

80. Singleton CB, Valenzuela SM, Walker BD, Tie H, Wyse KR, Bursill JA, Qui MR, Breit SN, Campbell TJ. Blockade by N-3 polyunsaturated fatty acid of the Kv4.3 current stably expressed in Chinese Hamster ovary cells. Brit J Pharmacol 1999, 127:941-948.

CV - T. Campbell 17

81. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela S, Qiu MR, Breit SN and Campbell TJ. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for inactivated state. Brit J Pharmacol 1999, 128; 444-450.

82. Singleton CB, Walker BD, Campbell TJ. N-3 polyunsaturated fatty acids and cardiac mortality. Aust NZ J Med 2000; 30(2): 246-251.

83. Tie, H, Walker BD, Valenzuela SM, Breit SN, Campbell TJ. The heart of psychotropic drug therapy. (Letter) Lancet 2000; 355: 1824-1825.

84. Tonini R, Ferroni A, Valenzuela S, Warton K, Campbell TJ, Breit SN, Mazzanti M. Characterisation of the NCC27 nuclear protein in stable transfected. FASEB J 2000; 14: 1171-1178.

85. Tie H, Walker BD, Singleton CB, Valenzuela SM, Bursill JA, Wyse KR, Breit SN, Campbell TJ. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol 2000; 140: 1967-75.

86. Campbell T, Harper W. Guidelines for unstable angina: evidence-based medicine in the information age (Editorial). Med. J. Aust. 2000; 173: 399-400.

87. Walker BD, Singleton CB, Tie H, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc Res 2000; 48: 44-58.

88. Valenzuela SM, Mazzanti M, Tonini R, Qiu MR, Warton K, Musgrove EA, Campbell TJ, Breit SN. The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle. J Physiol . 2000. 529: 541-551.

89. Campbell TJ. Update on the use of magnesium as an antiarrhythmic drug. Cardiac Electrophysiology Review 2000. 4: 251-254.

90. Tie H, Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ. Clozapine and sudden death. J Clin Psychopharmacol, 2001; 21: 630-632.

91. Vandenberg JI, Walker, BD, Campbell TJ. HERG K+ channels: friend and foe, Trends Pharmacol. Sci., 2001: 22; 240-246.

92. Baumann A.E. and Campbell, T.J. Heart week 2001: “Get active” a call to action. Med J. Aust. 2001; 174: 381-382.

93 Harrop, S.J., DeMaere,M.Z., Fairlie, W.D., Reztsova,T. Valenzuela, S.M. Mazzanti, M. Tonini, R. Qiu, M.R. Jankova, L. Warton, K. Bauskin,A.R., Wu, W.M. Pankhurst,S., Campbell, T.J. Breit, S.N., Curmi, P.M.G. Resolution of the Soluble Form of the Intracellular Chloride Ion Channel CLIC1 (NCC27). Crystal Structure at 1.4Ã J Biol Chem 2001; 276: 44993-45000.

94. Singarayar S, Singleton C, Tie H, Wyse K, Bursill J, Bauskin A, Wu W, Valenzuela S, Breit S, Campbell TJ. Components of Ischaemia and Kv4.3 Currents, J. Mol. Cell Cardiol 2002;34: 197-207.

95. Warton,K., Tonini,R., Fairlie,W.D., Matthews,J.M., Valenzuela,S.M., Qiu,M.R., Wu,W.M., Susan Pankhurst,S., Bauskin,A.R., Harrop,S.J., Campbell,T.J., Curmi,P.M.G., Breit,S.N., Mazzanti,M. Recombinant CLIC1 (NCC27) assembles in lipid bilayers via a pH-dependent two-state process to form chloride ion channels with identical characteristics to those observed in CHO cells expressing CLIC1. J.Biol.Chem.2002, 277: 26003-26011.

96. Qiu MR, Campbell TJ, and Breit SN.. A potassium ion channel is involved incytokine production by activated human macrophages. Clin Exp Immunol., 2002; 130; 67-74.

CV - T. Campbell 18

97. Singarayar, S. Bursill, J. Wyse, K. Bauskin, A. Wu, W. Vandenberg, J. Breit, S. Campbell, T. 2003. Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. J. Cardiovasc. Electrophysiol. 2003; 14: 641-650.

98. Campbell, T.J. and Macdonald, P.S. Digoxin in heart failure. Med. J. Aust. 179 (2): 98-102, 2003 .

99. Vandenberg, JI, Torres, AM, Campbell, TJ, Kuchel, PW. The HERGK+ channel: Progress in understanding the molecular basis of its unusual gating kinetics. Europ J. Biophys. 33: 89-97; 2004 (Epub ahead of print-Sept 10, 2003).

100. Torres, A, Bansal , PS, Sunde, M, Clarke, C, Bursill, JA, Smith, DJ, Bauskin, A, Breit, SN, Campbell, TJ, Alewood, P, Kuchell, PW, Vandenberg, JI. Structure of the HERG K+ channel S5P extracellular linker: Role of an amphipathic -helix in C-type inactivation. J. Biol.Chem. 2003; 278, 42136-42148.

101. Littler, D R, Harrop, SJ, Fairlie WD, Brown, LJ, Pankhurst, GJ, DeMaere, MZ, Campbell, TJ, Bauskin, AR, Tonini, R, Mazzanti, M, Breit, SN, Curmi, PM. The intracellular chloride ion channel protein CLIC1 undergoes a redox-controlled structural transition. J.Biol.Chem.2004 279:9298-9305.

102. Subbiah, RN, Clarke, CE, Smith, DJ, Zhao, JT, Campbell, TJ, and Vandenberg, JI. Molecular basis of slow activation of Human ether-a-go-go related gene (HERG) potassium channel. J. Physiol. 2004; 558 (Part 2), 417-431.

103. Subbiah, RN, Campbell, TJ, Vandenberg, JIV. Inherited cardiac arrhythmia syndromes: What have they taught us about arrhythmias and anti-arrhythmic therapy? Clin Exp Pharm Physiol 2004; 31: 906-912

104. Thompson, PL, Meredith, I, Amarena, J, Campbell, TJ, Sloman, JG, and Harris, PJ for the PACT Investigators. Effect of pravastatin compared with placebo initiated within 24 hours of the onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) Trial. Am. Heart J. 2004 148; e2-e8.

105. Kovacic, JC, Horton, MDA, Campbell, TJ, and Wilson, SL. Left atrial hematoma complicating inferior myocardial infarction. J Am Soc Echocardiography 2004; 17, 1201-3.

106. Subbiah,R N, Kondo,M, Campbell,TJ and Vandenberg, JI, Tryptophan scanning mutagenesis of the HERG K+ channel:The S4 domain is loosely packed and likely to be lipid exposed. J Physiol 2005; 569:367-379.

107. Campbell, T.J. Amiodarone Australian Prescriber 2005; 28: 150-154.

108. Clarke, C E, Hill, AP, Zhao, JT, Kondo, M, Subbiah, RN, Campbell, TJ and Vandenberg, JI Effect of S5P and alpha-helix charge mutants on inactivation of hERG K+ channels” J Physiol 2006; 573: 291-304.

109. Hill, A.P., Sunde, M., Campbell, T.J., Vandenberg, J.I. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 2007 92; 3915-29.

110. Hill, A.P., Campbell, T.J. Bansal P., Kuchel P. and Vandenberg J.I. The S631A mutation causes a mechanistic switch in the block of hERG channels by CnErg1. Biophys J 2007 (In press)

CV - T. Campbell 19

FULL PEER –REVIEWED PUBLICATIONS ARISING FROM MULTICENTRE TRIALS IN WHICH

DR CAMPBELL ACTED AS LOCAL CO-ORDINATOR

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.

2. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766.

3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.

4. ISIS-4 Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345, 669-685.

5. Design features and baseline characteristics of the LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) Study - Am J Cardiol 1995; 76: 474-479

6. Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent or remote myocardial infarction. Waldo AL, Camm AJ, de Ruyter H, et al for the SWORD Investigators. Lancet 348, 7-12, 1996.

7. The GUSTO llb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. 335, 775-782, 1996

8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996; 348: 1329-1339.

9. The PARAGON Investigators. International,randomized,controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation, 97, 2386-95, 1998.

10. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 339, 1349-1357, 1998.

11. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). European Heart J 1999; 20:1553-1562.

12. Cannon, C. P. et al, for the OPUS-TIMI 16 Investigators. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000; 102:149-56.

13. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban or both for secondary prevention after acute coronary syndromes. Circulation. 2001;103:1727-1733.

CV - T. Campbell 20

14. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. (EPHESUS Study). N. Engl. J. Med. 2003; 348: 1309-21.

15. Doughty, R.N., Whalley, G.A., Walsh, H.A., Gamble, G.D., Lopez-Sendon, J., Sharpe, N., on behalf of the CAPRICORN Echo substudy investigators. Effects of carvedilol on left ventricular remodelling after acute myocardial infact: The CAPRICORN Echo substudy. Circulation 2004; 109: 201 – 206.

16. Camm,AJ, Pratt, CM, Schwartz, PJ Al-Khalidi, HR Spyt, MJ Holroyde, MJ Karam, R Sonnenblick,EH Brum, JMGand on Behalf of the AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in Patients After a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification Circulation 2004; 109: 990-6.

CV - T. Campbell 21

CITATIONS OF FULL PAPERS as at March 2006

Source: Science Citation Index

Period Total Citation Count Self Citations

1973-1984 74 91985 37 21986 29 01987 69 61988 80 51989 121 21990 95 61991 110 91992 109 71993 84 141994 74 51995 53 01996 68 81997 66 21998 30 11999 16 12000 47 52001 34 22002 43 3

2003-March 2006 272 13Totals 1511 100

Most-cited paper:

Campbell, T.J. Cardiovasc Res 17, 344-352, 1983: 340 citations (including 11 self-citations).

ABSTRACTS & PAPERS IN NON PEER-REVIEWED JOURNALS

Not listed in the interests of space-can be provided if requested

CV - T. Campbell 22